HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Benzinga · 10/17 11:12
HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price target.